{rfName}
Co

Indexed in

License and use

Icono OpenAccess

Citations

12

Altmetrics

Analysis of institutional authors

Morón-Merchante IAuthor

Share

Publications
>
Clinical Guidelines

Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus.

Publicated to:Clinica e Investigacion en Arteriosclerosis. 30 Suppl 1 1-19 - 2018-07-01 30 Suppl 1(), DOI: 10.1016/j.arteri.2018.06.006

Authors: Ruiz-García A, Arranz-Martínez E, Morón-Merchante I, Pascual-Fuster V, Tamarit JJ, Trias-Villagut F, Pintó-Sala X, Ascaso JF, Grupo de Diabetes de la Sociedad Española de Arteriosclerosis

Affiliations

Consorcio Hosp Gen Univ, Valencia, Spain - Author
Ctr Salud San Blas, Madrid, Spain - Author
Univ Autonoma Madrid, Ctr Salud, Univ Goya, Madrid, Spain      Autonomous University of Madrid - Author
Univ Barcelona, Hosp Bellvitge, Barcelona, Spain      University of Barcelona    Bellvitge University Hospital    Catalan Health Institute - Author
Univ CEU Cardenal Herrera, Ctr Salud Palleter, Castellon de La Plana, Spain.      Universidad CEU Cardenal Herrera - Author
Univ CEU Cardenal Herrera, Ctr Salud Palleter, Castellon de La Plana, Spain      Universidad CEU Cardenal Herrera       - Author
Univ Europea Madrid, Ctr Salud, Unidad Lipidos & Prevenc Cardiovasc, Univ Pinto, Madrid, Spain      European University of Madrid       - Author
Univ Valencia, Hosp Clin, INCLIVA Res Inst, CIBERDEM,ISCIII, Valencia, Spain      University of Valencia    CIBERDEM    CIBER - Centro de Investigacion Biomedica en Red - Author
See more

Abstract

A consensus document of the Diabetes working group of the Spanish Society of Arteriosclerosis (SEA) is presented, based on the latest studies and conceptual changes that have appeared. It presents the cardiovascular risk in type 2 diabetes mellitus (T2DM) and the action guidelines for the prevention and treatment of cardiovascular disease (CVD) associated with T2DM. The importance of lipid control, based on the objective of LDL-C and non-HDL-C when there is hypertriglyceridemia, and the blood pressure control in the prevention and treatment of CVD is evaluated. The new hypoglycemic drugs and their effects on CVD are reviewed, as well as the treatment and control guidelines of hyperglycemia. Likewise, the use of antiplatelet agents is considered. Emphasis is placed on the importance of global and simultaneous action on all risk factors to achieve a significant reduction in cardiovascular events. This supplement is sponsored by Laboratorios Esteve, S.A.Copyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Keywords

AntiagregantesAntiplatelet agentsBlood-pressureCardiovascular diseaseCardiovascular riskChronic kidney-diseaseCoronary-heart-diseaseDiabetes tipo 2DislipidemiaDose statin therapyDyslipidemiaEnfermedad cardiovascularGlucose cotransporter-2 inhibitorsHipertension arterialHypertensionHypertensive patientsLowering ldl cholesterolMicrovascular outcomesRenal outcomesRiesgo cardiovascularType 2 diabetesVery-low levels

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinica e Investigacion en Arteriosclerosis, Q3 Agency Scopus (SJR), its regional focus and specialization in Cardiology and Cardiovascular Medicine, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.84, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-01, the following number of citations:

  • WoS: 5
  • Scopus: 7

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-01:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 61.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 95 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 15.7.
  • The number of mentions on the social network X (formerly Twitter): 20 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.